This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Low Doses of Controlled-Release Paroxetine in the Treatment of Late-Life Depression: A Randomized, Placebo-Controlled Trial

Mark Hyman Rapaport, R. Bruce Lydiard, Cornelius D. Pitts, Desiree Schaefer, Edward I. Bartolic, Malini Iyengar, Michelle Carfagno, and Alan Lipschitz

Published: October 7, 2008

Article Abstract

Objective: To evaluate the efficacy and tolerability of low daily doses of controlled-release (CR) paroxetine in patients with late-life depression.

Method: This was a 10-week, multicenter, placebo-controlled, double-blind, fixed-dose trial randomly assigning patients ≥ 60 years old to daily doses of paroxetine CR 12.5 mg (N = 168), paroxetine CR 25 mg (N = 177), or placebo (N = 180). Patients had major depressive disorder (DSM-IV criteria) and 17-item Hamilton Rating Scale for Depression (HAM-D) total scores of ≥ 18. The primary efficacy variable was the change from baseline to study endpoint in total HAM-D scores. The study was conducted from June 2003 to October 2004.

Results: The drug/placebo difference in HAM-D change from baseline at study endpoint was -1.8 (95% CI = -3.41 to -0.19, p =.029) for paroxetine CR 12.5 mg, and -3.3 (95% CI=-4.84 to -1.68, p

Conclusion: These data demonstrate that paroxetine CR 12.5 mg and 25 mg daily are efficacious and well tolerated in the treatment of major depressive disorder in patients ≥ 60 years of age, although effect sizes are relatively smaller with the 12.5 mg/day dose.

Volume: 69

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...